Cargando…
Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review
Synovial sarcoma (SS) is an aggressive malignancy which accounts for approximately 5–10% of all soft-tissue sarcomas. SS has pathologic and genomic characteristics that define it as a distinct subtype of soft tissue sarcoma (STS). STS subtypes continue to be recognized as distinct entities with spec...
Autores principales: | Riedel, Richard F., Jones, Robin L., Italiano, Antoine, Bohac, Chet, Thompson, Juliette C., Mueller, Kerstin, Khan, Zaeem, Pollack, Seth M., Van Tine, Brian A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267101/ https://www.ncbi.nlm.nih.gov/pubmed/30388821 http://dx.doi.org/10.3390/cancers10110417 |
Ejemplares similares
-
Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States
por: Pollack, Seth M., et al.
Publicado: (2020) -
Targeting cancer testis antigens in synovial sarcoma
por: Mitchell, Geoffrey, et al.
Publicado: (2021) -
Primary Intracranial Synovial Sarcoma
por: Patel, Mohit, et al.
Publicado: (2016) -
Primary renal synovial sarcoma
por: Bakhshi, Girish D., et al.
Publicado: (2012) -
The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients
por: Pollack, Seth M.
Publicado: (2017)